The company will co-promote Suncros brand across prescription and consumer channels to drive growth Sun Pharma will focus on dermatology as the fourth engine of growth for its OTC business. As part of this growth strategy, th
Headwinds plaguing the country's largest drug-maker Sun Pharmaceutical will continue for next two-three quarters owing to pricing pressures and regulatory issues dogging its Halol plant, says a report.
Sun Pharmaceutical Industries shares plunged nearly 6 per cent in late morning trade on Tuesday after the pharma company posted a weaker-than expected annual sales outlook as it grappled with increased competition in the Unit
Driven by a sharp rally in the stock market last week, the combined market valuation of top- 10 most valued Indian companies soared by a whopping Rs 98,598 crore, with ITC emerging as the biggest mover.
Sun Pharma shares rallied after it said that the umbrella pact and transaction agreements signed with Daiichi Sankyo and its overseas subsidiaries have been terminated due to divestment of Ranbaxy by the Japanese firm.
ICGEB will provide the technical know-how and pre-clinical expertise and Sun Pharma to develop this drug with appropriate pre-clinical & clinical studies to register it in India and other global markets